AmorChem invests in drug project to combat diabetic macular edema
AmorChem has made an undisclosed investment in a project led by Dr. Przemyslaw (Mike) Sapieha of Hôpital Maisonneuve that is focused on discovering new drugs for the treatment of diabetic macular edema. The deal is being done in partnership with Univalor, which facilitates commercialization and technology transfer on behalf of Québec universities and research institutions. Based in Montréal, AmorChem is an early stage life sciences fund managed by Canadian venture capital firm GeneChem. The fund invests in R&D-stage initiatives to enable pre-clinical proof-of-concept in a semi-virtual mode.
19 June 2014•4 mins read
